Implementation of the Prostate Cancer Prevention Trial (PCPT)

Controlled Clinical Trials

Volumn 25, Issue 2, 2004, Pages 203-222

  Goodman, Phyllis J ^a,e   Tangen, Catherine M ^a   Crowley, John J ^a   Carlin, Susan M ^a   Ryan, Anne ^b   Coltman Jr , Charles A ^c   Ford, Leslie G ^b   Thompson, Ian M ^d  

^a Box 19024 ^*  (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c University of Texas Health Science Center at San Antonio   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e Southwest Oncology Group   (United States)

Author keywords

Chemoprevention; Finasteride; Prostate cancer; Study management; Study organization

Indexed keywords

FINASTERIDE; PLACEBO; STEROID 5ALPHA REDUCTASE INHIBITOR;

CANCER PREVENTION; CLINICAL TRIAL; COMPUTER ANALYSIS; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG DISTRIBUTION; EXPERIMENTAL DESIGN; EXPERIMENTAL MODEL; HISTOLOGY; LEUKOCYTE; MONITORING; PATHOLOGY; PREVALENCE; PROSTATE CANCER; QUALITY CONTROL; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SAFETY;

EID: 1542321126     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2003.11.007     Document Type: Article

References (17)

1. Greenwald P., Kelloff G., Burch-Whitman C.et al. Chemoprevention. CA Cancer J. Clin. 45:1995;31-49.
2. Gormley G. Chemoprevention strategies for prostate cancer: the role of 5α-reductase inhibitors. J. Cell. Biochem., Suppl. 6H:1992;113-117.
3. Thompson I., Feigl P., Coltman C. Chemoprevention of prostate cancer with finasteride. DeVita V.T. Important advances in oncology. 1995;57-76 J.B. Lippincott, Philadelphia.
4. Thompson I.M., Coltman C.A., Brawley O.W.et al. Chemoprevention of prostate cancer. Semin. Urol. 13:1995;122-129.
5. Thompson I.M., Coltman C.A. Screening for prostate cancer: opportunities for prevention. Semin. Urol. Oncol. 14:1996;4-11.
6. Brawley O.M., Ford L.G., Thompson I.et al. 5-α-reductase inhibition of prostate cancer prevention. Cancer Epidemiol., Biomarkers Prev. 3:1994;177-182.
7. Habib G.K., Bissas A., Neill W.A.et al. Flow cytometric analysis of cellular DNA in human prostate cancer: relationship to 5-alpha-reductase activity of the tissue. Urol. Res. 17:1989;239-243.
8. Kadoham N., Karr J.P., Murphy G.P.et al. Selective inhibition of prostatic tumor 5 alpha-reductase by a 4-methyl-4-aza-steroid. Cancer Res. 44:1984;4947-4950.
9. Petrow V., Padilla G.M., Mukherji S.et al. Endocrine dependence of prostatic cancer upon dihydrotestosterone and not upon testosterone. J. Pharm. Pharmacol. 36:1984;352-353.
10. Gormley G.J., Stoner E., Bruskewitz R.C.et al. The effect of finasteride in men with benign prostatic hyperplasia. N. Engl. J. Med. 327:1992;1185-1191.
11. Feigl P., Blumenstein B., Thompson I.et al. Design of the Prostate Cancer Prevention Trial (PCPT). Control. Clin. Trials. 16:1995;150-163.
12. Catalona W.J., Smith D.S., Ratliff T.L.et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N. Engl. J. Med. 324:1991;1156-1161.
13. Brawer M.K., Chetner M.P., Beatie J.et al. Screening for prostatic carcinoma with prostate specific antigen. J. Urol. 147:1992;841-845.
14. Carter H.B., Pearson J.D., Metter E.J.et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 267:1992;2215-2220.
15. Cooner W.H., Mosley B.R., Rutherford C.L.et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J. Urol. 143:1990;1146-1152.
16. Guess H.A., Heyse J.A., Gormley G.G. The effect of finasteride on prostate specific antigen in men with benign prostatic hyperplasia. Prostate. 22:1993;31-37.
17. Moinpour C.M., Atkinson J.O., Thomas S.M.et al. Minority recruitment in the prostate cancer prevention trial. Ann. Epidemiol. 10(S8):2000;S85-S91.